Danielle Sullivan

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Robert L. Coleman, Gini F. Fleming, Mark F. Brady et al. · New England Journal of Medicine · 2019 · 886 citations · Full text

Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

Sibylle Loibl, Joyce O’Shaughnessy, Michael Untch et al. · The Lancet Oncology · 2018 · 744 citations

Breast Oncology, Parp Inhibitor Veliparib, Medicine +7

Relationships between Hippocampal Sharp Waves, Ripples, and Fast Gamma Oscillation: Influence of Dentate and Entorhinal Cortical Activity

Danielle Sullivan, Jozsef Csicsvari, Kenji Mizuseki et al. · Journal of Neuroscience · 2011 · 303 citations · Full text

Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

Mehra Golshan, Sibylle Loibl, Stephanie M. Wong et al. · JAMA Surgery · 2020 · 136 citations · Full text

Phase 3 study evaluating efficacy and safety of veliparib (V) plus carboplatin (Cb) or Cb in combination with standard neoadjuvant chemotherapy (NAC) in patients (pts) with early stage triple-negative breast cancer (TNBC).

Charles E. Geyer, Joyce O’Shaughnessy, Michael Untch et al. · Journal of Clinical Oncology · 2017 · 71 citations

Surgical Oncology, Breast Oncology, Immunology +16